

December 11, 2024

То	То
Listing Department,	The Corporate Relations Department
NATIONAL STOCK EXCHANGE OF INDIA LIMITED	BSE LIMITED
Exchange Plaza,	Phiroz Jeejeebhoy Towers,
Bandra Kurla Complex, Bandra (E),	25th floor, Dalal Street,
MUMBAI -400 051	MUMBAI -400 001
Company Code No. AUROPHARMA	Company Code No. 524804

Dear Sir / Madam,

Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

This is to inform you that Theranym Biologics Private Limited, a wholly owned subsidiary of the Company ("Theranym") has allotted 2,041 equity shares (2% of the post allotment equity share capital of Theranym) of Rs.10/- each to Dr. Satakarni Makkapati on preferential basis on December 11, 2024. Post allotment, Theranym ceased to be a wholly owned subsidiary of the Company and continue as a subsidiary of the Company.

The disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Part A of Schedule III of the aforesaid regulations, is attached as **Annexure**.

This is for your information and records.

Yours faithfully, For **AUROBINDO PHARMA LIMITED**

B. Adi Reddy Company Secretary

Enclosure: Annexure

(CIN: L24239TG1986PLC015190)

AUROBINDO PHARMA LIMITED

PAN No. AABCA7366H

Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India. Tel: +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.

Regd. off.: Plot No. 2, Maithrivihar, Ameerpet, Hyderabad-500038 Telangana, India Tel:+914023736370/23747340 Fax:+914023741080/23746833 Email: info@aurobindo.com Website: www.aurobindo.com



Annexure

(CIN: L24239TG1986PLC015190)

Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

а	the amount and percentage of the turnover or revenue or income and net worth contributed by such unit or division or undertaking or subsidiary or associate company of the listed entity during the last financial year;	The turnover of Theranym Biologics Private Limited, a wholly owned subsidiary of the Company ("Theranym") is as under:	
		Turnover for the FY ended 31.03.2024 : Nil (yet to start commercial operations)	
		Net-worth as on 31.03.2024 : Rs.7 lakhs	
b	date on which the agreement for sale has been entered into;	No agreement has been entered into.	
		Theranym has allotted 2,041 equity shares of Rs.10 each to Dr. Satakarni Makkapati through preferential issue of equity shares on 11.12.2024.	
		Post allotment of 2,041 equity shares of Rs.10 each to Dr. Satakarni Makkapati, Theranym ceased to be a wholly owned subsidiary of the Company and continue as a subsidiary of the Company. Post allotment, following is the shareholding pattern of Theranym:	
		Name of the Shareholder	% of holding
		Aurobindo Pharma Limited	98%
		(Holding company)	
		Dr. Satakarni Makkapati	2%
С	the expected date of completion of sale/disposal;	Not applicable	
d	consideration received from such sale/disposal;	2,041 equity shares of Rs.10 each allotted by Theranym for a cash consideration of Rs.10/- per share aggregating to Rs.Rs.20,410/-	
е	brief details of buyers and whether any of the buyers belong to the promoter/ promoter group/group companies. If yes, details thereof;	Dr. Satakarni Makkapati does not belong to the promoter/ promoter group / group companies.	
f	whether the transaction would fall within related party transactions? If yes, whether the same is done at "arm's length";	Dr. Satakarni Makkapati is a director of Theranym and Aurobindo Pharma Limited. As per the SEBI (LODR) Regulations, 2015, the issue of specified securities on a preferential basis is not a related party transaction.	
g	whether the sale, lease or disposal of the undertaking is outside Scheme of Arrangement? If yes, details of the same including compliance with regulation 37A of LODR Regulations.	Not applicable	
h	additionally, in case of a slump sale, indicative disclosures provided for amalgamation/ merger, shall be disclosed by the listed entity with respect to such slump sale.	Not applicable	

AUROBINDO PHARMA LIMITED

PAN No. AABCA7366H

Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India. Tel: +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.

Regd. off.: Plot No. 2, Maithrivihar, Ameerpet, Hyderabad-500 038 Telangana, India Tel:+914023736370/23747340 Fax:+914023741080/23746833 Email: info@aurobindo.com Website: www.aurobindo.com